Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
New England Journal of Medicine2014Vol. 370(3), pp. 211–221
Citations Over TimeTop 1% of 2014 papers
Mark Sulkowski, David Gardiner, M. Rodríguez‐Torres, K. Rajender Reddy, Tarek Hassanein, Ira M. Jacobson, Eric Lawitz, Anna S. Lok, Federico Hinestrosa, Paul J. Thuluvath, Howard Schwartz, David R. Nelson, Gregory T. Everson, Timothy Eley, Megan Wind‐Rotolo, Shu-Pang Huang, Min Gao, Dennis Hernandez, Fiona McPhee, Diane L. Sherman, R. Hindes, William T. Symonds, C Pasquinelli, Dennis M. Grasela
Abstract
Once-daily oral daclatasvir plus sofosbuvir was associated with high rates of sustained virologic response among patients infected with HCV genotype 1, 2, or 3, including patients with no response to prior therapy with telaprevir or boceprevir. (Funded by Bristol-Myers Squibb and Pharmasset (Gilead); A1444040 ClinicalTrials.gov number, NCT01359644.).
Related Papers
- → The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir(2018)19 cited
- → Effect of Minor Populations of NS5A and NS5B Resistance-Associated Variants on HCV Genotype-3 Response to Daclatasvir plus Sofosbuvir, with or without Ribavirin(2016)23 cited
- → Effects of resistance‐associated variants in genotype 2 hepatitis C virus on viral replication and susceptibility to antihepatitis C virus drugs(2019)10 cited
- [RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS].(2015)
- → Editorial: sofosbuvir plus daclatasvir for the treatment of hepatitis C—can one size fit all?(2018)